

**Kyowa Hakko Kirin Co., Ltd.****Appendix to the Fiscal 2011 Interim Consolidated Financial Statements**

Interim results for Fiscal 2011  
(January 1, 2011 - June 30, 2011)

<b>Index</b>	<b>Page</b>
I. Consolidated Financial Results	
1. Income	1
2. Results by segment	1
3. Non-operating income/expenses	2
4. Extraordinary income/loss	2
5. R&D expenses	2
6. Capital expenditure	3
7. Depreciation expenses	3
8. Employee numbers	3
9. Exchange rates	3
II. Consolidated Subsidiaries and Affiliates	4
III. Non-Consolidated Net Sales by Division	5
1. Kyowa Hakko Kirin	5
2. Kyowa Hakko Bio	6
3. Kyowa Hakko Chemical	6
R&D Pipeline	7

This document was made as a supplement to the Kessan Tanshin (financial report) for the interim period of the fiscal year ending December 31, 2011. This document contains forward-looking statements based on a number of assumptions and beliefs made by management in light of information currently available. For a variety of reasons, actual financial results may differ materially from the forecasts presented here.

## I. Consolidated Financial Results

### 1. Trends in income

Millions of yen, rounded down

	January 1, 2010 to December 31, 2010 results			FY 2011 results				FY 2011 forecasts
	January 1 to March 31	January 1 to June 30 (A)	January 1 to December 31	January 1 to March 31	January 1 to June 30 (B)	Change on January to June 2010		January to December
						Amount (B-A)	%	
<b>Net sales</b>	99,256	203,466	413,738	114,862	186,367	(17,098)	92%	342,000
<b>Gross Profit</b>	44,100	92,763	190,979	56,644	100,234	7,470	108%	--
Selling, general and administrative expenses	32,572	71,071	145,568	34,734	70,297	(773)	99%	--
<b>Operating income (prior to amortization of goodwill)</b>	13,853	26,344	54,713	24,235	34,576	8,231	131%	52,767
<b>Operating income</b>	11,527	21,692	45,410	21,909	29,936	8,244	138%	43,500
Non-operating income	963	3,120	5,201	1,280	1,316	(1,804)		--
Non-operating expenses	550	2,478	4,111	937	1,040	(1,438)		--
<b>Ordinary income</b>	11,940	22,334	46,500	22,252	30,212	7,878	135%	44,500
Extraordinary income	--	1,082	2,822	8,265	8,421	7,338		--
Extraordinary loss	577	5,775	7,023	3,214	5,363	(412)		--
<b>Net income before income taxes</b>	11,363	17,641	42,299	27,304	33,270	15,629	189%	46,500
Corporate, local and enterprise taxes	5,366	7,718	20,040	12,496	15,507	7,789		--
Income from minority interests	(57)	21	61	22	44	23		--
<b>Net income</b>	6,053	9,901	22,197	14,785	17,718	7,816	179%	25,500
EPS before goodwill amortization (¥/share)	14.71	25.55	55.29	30.03	39.24			61.02

1. On April 21, 2011, Kyowa Hakko Kirin acquired all outstanding shares of ProStrakan Group plc and as a result ProStrakan Group, and its ten subsidiaries were newly included in the scope of consolidation. In terms of accounting treatment, June 30, 2011 will be considered as the date that the acquisition was completed and therefore results from ProStrakan have not been included in the consolidated financial results for the first half of the current fiscal year. Financial results from ProStrakan as of July have been included in the FY2011 Forecast.

2. Figures for FY2011 Forecast are those as announced July 20, 2011.

### 2. Trends in results by segment

#### (1) Results by operating segment

Millions of yen, rounded down

	January 1, 2010 to December 31, 2010 results			FY 2011 results				FY 2011 forecasts
	January 1 to March 31	January 1 to June 30 (A)	January 1 to December 31	January 1 to March 31	January 1 to June 30 (B)	Change on January to June 2010		January to December
						Amount (B-A)	%	
<b>Net sales</b>	99,256	203,466	413,738	114,862	186,367	(17,098)	92%	342,000
Pharmaceuticals	49,674	103,475	210,362	63,393	112,534	9,059	109%	225,000
Bio-Chemicals	22,213	44,186	84,236	19,686	40,360	(3,826)	91%	80,000
Chemicals	30,281	61,289	130,018	33,550	33,550	(27,739)	--	33,550
Other	2,493	5,082	10,499	2,651	5,306	224	104%	11,000
Total	104,662	214,034	435,116	119,281	191,752	(22,282)	90%	349,550
Eliminations	(5,406)	(10,567)	(21,377)	(4,419)	(5,384)	5,183	--	(7,550)
<b>Operating income</b>	11,527	21,692	45,410	21,909	29,936	8,244	138%	43,500
<i>*Before goodwill amortization</i>	13,853	26,344	54,713	24,235	34,576	8,231	131%	52,767
Pharmaceuticals	9,678	17,993	35,857	18,419	25,145	7,151	140%	37,500
Bio-Chemicals	11,835	22,307	44,485	20,576	29,459	7,151	132%	46,129
Chemicals	1,010	1,853	3,275	1,272	2,519	665	136%	3,500
Other	1,166	2,166	3,901	1,428	2,832	665	131%	4,126
Chemicals	674	1,589	5,678	2,135	2,135	546	--	2,135
Other	686	1,614	5,728	2,147	2,147	533	--	2,147
Other	82	150	363	82	148	(2)	98%	365
Other	82	150	363	82	148	(2)	98%	365
Total	11,446	21,587	45,175	21,909	29,948	8,361	139%	43,500
Eliminations	13,772	26,239	54,478	24,235	34,588	8,349	132%	52,767
Eliminations	81	105	235	0	(12)	(117)	--	--

Notes:

- Figures representing amounts before goodwill amortization have been italicized.
- As of the period under review, Kyowa Hakko Kirin has adopted "Accounting Standards Related to the Disclosure of Segment Information". Since the segment classification methods used to classify business by segment are the same as those used previously, we are able to make comparisons with the previous year.
- The Chemicals Business was discontinued at the end of the first quarter following the transfer of all shares of Kyowa Hakko Chemical on March 31, 2011. As a result, income from Chemicals was consolidated on the Statements of Income only until March 31, 2011.

## (2) Regional sales

Millions of yen, rounded down

	January 1, 2010 to December 31, 2010 results						FY 2011 results			
	January 1 to March 31	Percentage of consolidated sales	January 1 to June 30	Percentage of consolidated sales	January 1 to December 31	Percentage of consolidated sales	January 1 to March 31	Percentage of consolidated sales	January 1 to June 30	Percentage of consolidated sales
<b>Japan sales</b>	79,301	79.9%	161,229	79.2%	328,596	79.4%	91,329	79.5%	148,987	79.9%
<b>Overseas sales</b>	19,955	20.1%	42,236	20.8%	85,141	20.6%	23,532	20.5%	37,379	20.1%
America	5,162	5.2%	12,977	6.4%	23,467	5.7%	6,837	6.0%	10,456	5.6%
Europe	5,687	5.7%	10,779	5.3%	21,477	5.2%	6,060	5.3%	10,919	5.9%
Asia	8,991	9.1%	18,114	8.9%	39,689	9.6%	10,499	9.1%	15,772	8.5%
Other regions	113	0.1%	364	0.2%	507	0.1%	135	0.1%	231	0.1%
<b>Total consolidated net sales</b>	<b>99,256</b>	<b>100.0%</b>	<b>203,466</b>	<b>100.0%</b>	<b>413,738</b>	<b>100.0%</b>	<b>114,862</b>	<b>100.0%</b>	<b>186,367</b>	<b>100.0%</b>

## 3. Trends in non-operating income/expenses

Millions of yen, rounded down

	January 1, 2010 to December 31, 2010 results			FY 2011 results	
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31	January 1 to June 30
<b>Non-operating income</b>	963	3,120	5,201	1,280	1,316
Interest income	97	221	362	65	193
Dividends income	49	485	844	57	303
Foreign exchange gains	36	--	--	579	112
Gain on revaluation of derivatives	--	685	414	--	--
Equity in earnings of affiliates	337	626	1,074	166	141
Other	442	1,102	2,505	411	565
<b>Non-operating expenses</b>	550	2,478	4,111	937	1,040
Interest expenses	69	122	199	43	77
Foreign exchange loss	--	1,143	1,280	--	--
Loss on revaluation of derivatives	--	--	--	431	32
Loss on disposal of non-current assets	243	608	1,493	165	313
Other	237	604	1,138	296	617

## 4. Trends in extraordinary income / loss

Millions of yen, rounded down

	January 1, 2010 to December 31, 2010 results			FY 2011 results	
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31	January 1 to June 30
<b>Extraordinary income</b>	--	1,082	2,822	8,265	8,421
Gain on sales of subsidiaries and affiliates' stocks	--	--	--	8,265	8,320
Reversal of allowance for doubtful accounts	--	107	139	--	100
Gain on sale of investment securities	--	120	1,828	--	--
Gain on negative goodwill	--	854	854	--	--
<b>Extraordinary loss</b>	577	5,775	7,023	3,214	5,363
Loss on valuation of investment securities	--	2,588	1,473	1,546	3,043
Advisory fee	--	--	--	973	1,030
Loss on adjustment for changes of accounting standard for asset retirement	--	--	--	447	447
Loss on disaster	--	--	--	118	302
Loss on liquidation of subsidiaries and affiliates	--	--	--	--	209
Impairment loss	--	--	1,374	--	200
Provision for point card certificates for prior periods	--	--	--	128	128
Loss on revision of retirement benefit plan	577	1,771	1,771	--	--
Non-recurring depreciation on non-current assets	--	1,225	1,225	--	--
Provision for environmental measures	--	--	887	--	--
Other	--	189	290	--	--

## 5. Trends in R&amp;D expenses

Billions of yen, rounded down

	January 1, 2010 to December 31, 2010 results			FY 2011 results		FY 2011 forecasts
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31	January 1 to June 30	January to December
<b>R&amp;D (Consolidated)</b>	9.1	21.4	44.2	10.8	22.2	48.5
R&D to net sales ratio	9.2%	10.5%	10.7%	9.4%	11.9%	14.2%
Pharmaceuticals	8.1	19.3	40.0	9.8	20.4	45.0
(R&D to net sales ratio)	16.4%	18.7%	19.0%	15.6%	18.2%	20.0%
Bio-Chemicals	0.7	1.5	3.2	0.7	1.5	3.3
Chemicals	0.2	0.4	1.0	0.2	0.2	0.2
Other	--	--	--	--	--	--

## 6. Trends in capital expenditure (Tangible fixed assets)

Billions of yen, rounded down

	January 1, 2010 to December 31, 2010 results			FY 2011 results		FY 2011 forecasts
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31	January 1 to June 30	January to December
<b>Capital expenditure (Consolidated)</b>	5.5	12.2	21.9	3.1	5.9	18.3
Pharmaceuticals	4.3	7.0	11.7	1.4	2.8	8.4
Bio-Chemicals	0.9	3.7	7.5	1.3	2.7	9.6
Chemicals	0.2	1.3	2.5	0.3	0.3	0.3
Other	0.0	0.0	0.0	0.0	0.0	0.0

## 7. Trends in depreciation expenses

Billions of yen, rounded down

	January 1, 2010 to December 31, 2010 results			FY 2011 results		FY 2011 forecasts
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31	January 1 to June 30	January to December
<b>Depreciation expenses (Consolidated)</b>	4.2	10.5	22.1	5.5	10.4	23.0
Pharmaceuticals	1.9	4.5	10.7	3.3	6.8	15.7
Bio-Chemicals	1.2	3.8	6.7	1.2	2.6	6.2
Chemicals	1.0	2.1	4.6	0.9	0.9	0.9
Other	0.0	0.0	0.0	0.0	0.0	0.0

## 8. Employee numbers

	January 1, 2010 to December 31, 2010 results			FY 2011 results	
	As of March 31	As of June 30	As of December 31	As of March 31	As of June 30
<b>Employee numbers (Consolidated)</b>	7,362	7,554	7,484	6,818	7,305
Pharmaceuticals			5,041		
Bio-Chemicals			1,581		
Chemicals			652		
Other			210		

## 9. Exchange rates

	January 1, 2010 to December 31, 2010 results			FY2011 results		FY 2011 forecasts
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31	January 1 to June 30	January 1 to December 31
US Dollar (¥/US\$)	91	91	88	82	82	82
Euro (¥/Euro)	126	121	116	113	115	118
Pound (¥/Pound)	142	139	136	132	133	131

## II. Consolidated Subsidiaries and Affiliates

(As of June 30, 2011)

Segment	Type	Region	Company name	Percentage owned (direct and indirect)	Principal business	
Pharmaceuticals	Consolidated subsidiary	Japan	Kyowa Medex Co., Ltd.	100.0%	Manufacture and sale of diagnostic reagents	
			Kyowa Medical Promotion Co., Ltd.	100.0%	Manufacture and sale of pharmaceuticals	
		The Americas	Kyowa Hakko Kirin America, Inc.	100.0%	Holding company for administration and management of US subsidiaries (US)	
			BioWa, Inc.	100.0%	Out-licensing and promotion of anti-body technology (US)	
			Kyowa Hakko Kirin Pharma, Inc.	100.0%	Development of outsourced pharmaceutical products (US)	
			Kyowa Hakko Kirin California, Inc.	100.0%	Generate new candidate substances and develop pharmaceuticals (US)	
			Hematech, Inc.	100.0%	Technology research for manufacture of therapeutic antibody (US)	
			Hematech-GAC Venture, LLC	51.0%	Technology research for manufacture of therapeutic antibody (US)	
			ProStrakan Inc.	100.0%	Sales of pharmaceuticals (US)	
		Europe	ProStrakan Group plc	100.0%	Supervision and management of subsidiaries (UK)	
			Strakan International Limited	100.0%	Sales, licensing-in and licensing-out of pharmaceuticals (UK)	
			Strakan Pharmaceuticals Limited	100.0%	Development of pharmaceuticals (UK)	
			ProStrakan Limited	100.0%	Sales of pharmaceuticals (UK)	
			ProStrakan Pharma S.A.S.	100.0%	Sales of pharmaceuticals (France)	
			ProStrakan Farmaceutical SLU	100.0%	Sales of pharmaceuticals (Spain)	
			ProStrakan Pharma GmbH	100.0%	Sales of pharmaceuticals (Germany)	
			ProStrakan Holdings B.V.	100.0%	Holding company for special companies (Netherlands)	
			ProStrakan Pharma B.V.	100.0%	Sales of pharmaceuticals (Netherlands)	
			ProStrakan S.r.l.	100.0%	Sales of pharmaceuticals (Italy)	
		Kyowa Hakko Kirin Italia S.r.l.	100.0%	Sales of pharmaceuticals (Italy)		
		Asia	Kirin Kunpeng (China) Bio- Pharmaceutical Co., Ltd.	100.0%	Manufacture and sale of pharmaceuticals (China)	
			Jeil-Kirin Pharmaceutical Inc.	90.0%	Sales of pharmaceuticals (Korea)	
			Kyowa Kirin Pharmaceuticals (Taiwan) Co., Ltd.	100.0%	Sales of pharmaceuticals (Taiwan)	
			Kyowa Hakko Kirin (Hong Kong) Co., Ltd.	100.0%	Sales of pharmaceuticals (Hong Kong)	
			Kyowa Hakko Kirin (Singapore) Pte. Ltd.	100.0%	Sales of pharmaceuticals (Singapore)	
		Affiliate accounted for by the equity method	Europe	ProStrakan AB	50.0%	Sales of pharmaceuticals (Sweden)
		Bio-Chemicals	Consolidated subsidiary	Japan	Kyowa Hakko Bio Co., Ltd.	100.0%
Daiichi Fine Chemical Co., Ltd.	100.0%				Manufacture and sale of active pharmaceutical ingredients and pharmaceutical intermediates	
Kyowa Wellness Co., Ltd.	100.0%				Sale of healthcare products	
Kyowa Engineering Co., Ltd.	100.0%				Design and installation of plant facilities and equipment	
The Americas	Biokyowa Inc.			100.0%	Manufacture and sale of amino acids (US)	
	Kyowa Hakko U.S.A., Inc.			100.0%	Sale and import/export of fine chemicals including amino acids (US)	
	Kyowa Hakko Bio U.S. Holdings, Inc.			100.0%	Holding company for administration and management of US subsidiaries (US)	
Europe	Kyowa Hakko Europe GmbH			100.0%	Sale and import/export of fine chemicals including amino acids (Germany)	
	Kyowa Hakko Bio Italia S.r.l.			100.0%	Sale and import/export of fine chemicals including amino acids (Italy)	
Asia	Shanghai Kyowa Amino Acid Co., Ltd.			70.0%	Manufacture and sale of amino acids (China)	
	Kyowa Hakko (H.K.) Co., Ltd.			100.0%	Sale and import/export of fine chemicals including amino acids (Hong Kong)	
	Kyowa Hakko Bio Singapore Pte. Ltd.	100.0%	Sale and import/export of fine chemicals including amino acids (Singapore)			
Other	Consolidated subsidiary	Japan	Chiyoda Kaihatsu Co., Ltd.	100.0%	Transportation, insurance, wholesale sales of food, etc.	
	Affiliate accounted for by the equity method		Japan Synthetic Alcohol Co., Ltd.	33.3%	Manufacture and sale of industrial use alcohol	

Notes: Changes to the scope of consolidation (January 1, 2011 to June 30, 2011)

Newly consolidated: 11 companies: ProStrakan Group plc and 10 subsidiaries (\*1)

Removed: 4 companies: Kashiwagi Corporation (\*2), Kyowa Hakko Chemical Co., Ltd., Miyako Kagaku Co., Ltd. (\*3), Shinwa Pharmaceutical Co., Ltd. (\*4)

\*1 On April 21, 2011, Kyowa Hakko Kirin acquired all outstanding shares of ProStrakan Group plc and as a result ProStrakan Group, and its 10 subsidiaries were newly included in the scope of consolidation.

\*2 As of January 1, 2011, Kashiwagi Corporation was merged with Miyako Kagaku Co., Ltd. and eliminated.

\*3 Kyowa Hakko Chemical Co., Ltd. and its subsidiary Miyako Kagaku Co., Ltd. were removed from the scope of consolidation at the end of the first quarter of the current period following the transfer of all shares of Kyowa Hakko Chemical Co., Ltd. to KJ Holdings Inc. on March 31, 2011.

\*4 Shinwa Pharmaceutical Co., Ltd. was removed from the scope of consolidation as of the second quarter of the current period and all shares in the company were transferred on April 1, 2011.

### III. Non-Consolidated Net Sales by Division (Items and main products)

#### 1. Kyowa Hakko Kirin

Billions of yen, rounded down

Pharmaceuticals division (non-consolidated)	January 1, 2010 to December 31, 2010 results			FY2011 results			FY 2011 forecasts
	January 1 to March 31	January 1 to June 30 (A)	January 1 to December 31	January 1 to March 31	January 1 to June 30 (B)	Change on January 1 to June 30 (B/A)	January 1 to December 31
<b>Pharmaceuticals division total</b>	<b>45.3</b>	<b>94.1</b>	<b>192.9</b>	<b>59.8</b>	<b>104.6</b>	<b>111%</b>	<b>201.2</b>
<b>Indication / Product</b>							
<i>ESA formulation</i> <b>Nesp</b>	7.7	17.7	41.7	11.9	25.4	144%	50.8
<i>ESA formulation</i> <b>Espo</b>	2.7	5.7	10.8	1.3	2.7	48%	5.3
<b>Nesp/Espo</b>	10.3	23.4	52.6	13.3	28.2	120%	56.1
<i>Secondary hyperparathyroidism</i> <b>Regpara</b>	1.9	4.3	9.5	2.5	5.3	124%	11.1
<i>Antiallergenic</i> <b>Allelock</b>	8.2	13.9	26.8	13.7	18.1	130%	29.0
<i>Antiallergenic</i> <b>Celtect</b>	0.7	1.4	2.7	0.7	1.3	95%	2.3
<i>Antiallergic eyedrops</i> <b>Patanol</b>	3.5	4.7	7.5	7.3	8.6	183%	11.6
<i>G-CSF</i> <b>Gran/Neu-up*1</b>	3.3	7.3	14.4	3.3	6.7	93%	14.5
<i>Cancer pain</i> <b>Fentos*2</b>	--	0.0	0.8	0.4	1.2	--	2.6
<i>Anticancer</i> <b>Farmorubicin*3 / Adriacin</b>	1.1	2.4	4.8	0.2	0.5	22%	
<i>Anticancer</i> <b>5 – FU</b>	0.7	1.5	3.1	0.7	1.5	100%	2.9
<i>Anticancer</i> <b>Navelbine</b>	0.5	1.0	2.0	0.4	0.8	86%	1.6
<i>Cardiovascular</i> <b>Coniel</b>	4.8	10.3	21.0	4.6	9.6	93%	19.7
<i>Cardiovascular (Hypertension)</i> <b>Coversyl</b>	0.9	2.0	4.2	0.9	1.9	94%	3.9
<i>Cardiovascular</i> <b>Inovan / Pre Dopa</b>	0.7	1.5	3.0	0.7	1.3	92%	2.9
<i>Antiepileptic</i> <b>Depakene</b>	2.3	5.2	11.0	2.6	5.3	102%	11.1
<i>Parkinson's disease</i> <b>Permax*4</b>	--	0.7	2.0	0.5	1.1	149%	2.3
<i>Gastrointestinal</i> <b>Nauzelin</b>	1.3	2.6	5.3	1.2	2.3	88%	4.9
<i>Inflammatory bowel disease</i> <b>Asacol</b>	0.0	0.2	0.7	0.5	1.1	506%	2.8
<b>Exports and Technology Out-Licensing</b>	5.5	13.1	24.1	7.6	11.4	87%	22.4

Notes 1: As of March 1, 2010, manufacturing, sales and other rights for Neu-up were transferred to Yakult Honsha.

Therefore, Gran/Neu-up figures after March 31, 2010 include only sales figures for Gran.

2: Sales of Fentos began June 24, 2010.

3: Sales of Farmorubicin ended December 31, 2010 following completion of our contract with Pfizer.

Therefore, as of January 2011, only amounts for Adriacin have been included in Farmorubicin/Adriacin.

4: Sales of Permax began April 1, 2010.

## 2. Kyowa Hakko Bio

Billions of yen, rounded down

Bio-Chemicals division (non-consolidated)	January 1, 2010 to December 31, 2010 results			FY2011 results			FY 2011 forecasts
	January 1 to March 31	January 1 to June 30 (A)	January 1 to December 31	January 1 to March 31	January 1 to June 30 (B)	Change on January 1 to June 30 (B/A)	January 1 to December 31
<b>Bio-Chemical division total</b>	14.8	28.7	54.2	12.3	25.9	90%	50.9
<b>Pharmaceuticals / Industrial raw materials</b>							
<b>Amino acids</b>	5.5	10.8	20.4	4.5	10.1	94%	19.7
<b>Nucleic acids and vitamins</b>	1.3	2.5	4.8	1.2	2.7	107%	5.2
<b>Other</b>	2.1	3.9	8.0	1.7	3.8	97%	7.2
<b>Health care products</b>	2.3	4.9	9.8	2.1	4.7	94%	9.3

## 3. Kyowa Hakko Chemical

Billions of yen, rounded down

Chemicals division (non-consolidated)	January 1, 2010 to December 31, 2010 results			FY2011 results
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31
<b>Chemicals division total</b>	19.3	39.7	85.7	22.9
<b>Solvents</b>	7.4	15.9	33.4	8.4
<b>Raw materials for plasticizers</b>	6.3	12.2	27.7	7.7
<b>Specialty chemicals</b>	4.6	9.9	21.2	5.9

Note: The Chemicals Business was discontinued at the end of the first quarter following the transfer of all shares of Kyowa Hakko Chemical on March 31, 2011. As a result, income from Chemicals are until the first quarter ended March 31, 2011.

## R&D PIPELINES

Filed • Approved

Aug 2nd 2011

Therapeutic area	Code Name Generic Name	Mechanism of action	Stage		Indication	Formulation	In-house or Licensed	Remarks
			Japan	Other countries				
Oncology	<b>KW-0761</b>	Anti-CCR4 humanized antibody	Filed Apr/2011		Adult T-cell leukemia/lymphoma	Injection	Developed In-house	(※) POTELLIGENT®
	<b>KRN321 Darbepoetin Alfa</b>	Long-acting Erythropoiesis stimulating agent	Filed Nov/2008		☆ Chemotherapy induced anemia	Injection	Kirin-Amgen	Launched for anemia of CKD patients
	<b>Pegfilgrastim</b>	Long-acting Granulocyte colony stimulating factor		Filed in Asia	Chemotherapy induced febrile neutropenia	Injection	Kirin-Amgen	Asia: Korea, Taiwan and Vietnam
Nephrology	<b>Cinacalcet Hydrochloride</b>	Calcium receptor agonist		Filed in Singapore	Secondary hyperparathyroidism	Oral	Licensed from NPS	Japan: Launched
	<b>Darbepoetin Alfa</b>	Long-acting Erythropoiesis stimulating agent		Approved in Asia	Renal Anemia (on dialysis)	Injection	Kirin-Amgen	Approved in Thailand on May 25 (Filed in Singapore and Philippines)
CNS	<b>KW-6500 Apomorphine Hydrochloride</b>	Dopamine receptor agonist	Filed Jul/2011		Parkinson's disease	Injection	Licensed from Britannia Pharmaceuticals Limited	
Other	<b>AMG531 Romiplostim</b>	Thrombopoietin receptor agonist		Approved in Asia	Idiopathic (Immune) thrombocytopenic purpura	Injection	Kirin-Amgen	Approved in Korea on June 1st (Filed in Singapore, Hong Kong, Malaysia and Taiwan)

### Phase II, Phase III

Therapeutic area	Code Name Generic Name	Mechanism of action	Stage		Indication	Formulation	In-house or Licensed	Remarks
			Japan	Other countries				
Oncology	<b>KW-0761</b>	Anti-CCR4 humanized antibody		Phase I / II in USA	Peripheral T-cell lymphoma and cutaneous T-cell lymphoma	Injection	Developed In-house	(※) POTELLIGENT®
			Phase II		Adult T-cell leukemia/lymphoma, Add-on therapy (for untreated patients)			
			Phase II		Peripheral T/NK-cell Lymphoma			
	<b>KW-2246 Fentanyl citrate</b>	μ-opioid receptor agonist	Phase III		Cancer pain	Sublingual tablet	Licensed from Orexo	
	<b>KRN125 Pegfilgrastim</b>	Long-acting Granulocyte colony stimulating factor	Phase III		Chemotherapy induced febrile neutropenia	Injection	Kirin-Amgen	
	<b>ARQ 197</b>	c-Met inhibitor	Phase II	Phase II in Korea	Gastric cancer	Oral	Licensed from ArQule	
Phase I				Lung cancer				
Nephrology	<b>KRN321 Darbepoetin Alfa</b>	Long-acting Erythropoiesis stimulating agent	Phase III		☆ Paediatric Renal Anemia	Injection	Kirin-Amgen	Launched in Japan for anemia of CKD patients
				Phase II in China	Renal Anemia (on dialysis)			
	<b>Cinacalcet Hydrochloride</b>	Calcium receptor agonist		Phase III in China	Secondary hyperparathyroidism	Oral	Licensed from NPS	Japan: Launched
Immunology/Allergy	<b>ASKP1240</b>	Anti-CD40 fully human monoclonal antibody	Phase I	Phase II in USA	Organ transplant rejection	Injection	Developed In-house	Jointly developed with Astellas
	<b>Z-206 Mesalazine</b>	pH dependent controlled release tablet	Phase II		☆ Crohn's disease	Oral	Licensed from Zeria Pharma.	Jointly developed with Zeria Pharma Launched in Japan for ulcerative colitis.
CNS	<b>KW-6002 Istradefylline</b>	Adenosine A2a receptor antagonist	Phase III		Parkinson's disease	Oral	Developed In-house	Reimbursement of license from Valeant International SRL for the development and commercialization of KW-6002 in the US and Canada.
	<b>KW-6485 Topiramate</b>	Antiepileptic drugs	Phase III		☆ Pediatric epilepsy	Oral	Licensed from JANSSEN PHARMACEUTICAL K.K.	Launched in Japan for use as an epileptic drug
Other	<b>KW-3357 Antithrombin</b>	Recombinant human antithrombin	Phase III	Phase I in Europe	Disseminated intravascular coagulation, Congenital antithrombin deficiency	Injection	Developed In-house	

### Phase I

Therapeutic area	Code Name Generic Name	Mechanism of action	Stage		Indication	Formulation	In-house or Licensed	Remarks
			Japan	Other countries				
Oncology	<b>KW-2450</b>	IGF-1 receptor signal inhibitor		Phase I / II in USA	Cancer	Oral	Developed In-house	
	<b>KRN330</b>	Anti-A33 fully human antibody		Phase I / II a in USA	Cancer	Injection	Developed In-house	
	<b>B1W-8962</b>	Anti-GM2 humanized antibody		Phase I / II a in USA	Cancer	Injection	Developed In-house	POTELLIGENT®
	<b>KRN951 Tivozanib</b>	VEGF receptor inhibitor	Phase I		Cancer	Oral	Developed In-house	
	<b>KHK2866</b>	Anti-HB-EGF humanized antibody		Phase I in USA	Cancer	Injection	Developed In-house	POTELLIGENT®
	<b>LY2523355 Litronesib</b>	M phase kinesin Eg5 inhibitor	Phase I		Cancer	Injection	Developed In-house	World wide outlicensed to Eli Lilly for the development and commercialization of LY2523355 except Japan
Nephrology	<b>RTA 402 Bardoxolone Methyl</b>	Antioxidant Inflammation Modulator	Phase I		Diabetic nephropathy	Oral	Licensed from Reata	
Immunology/Allergy	<b>KHK4563 Benralizumab</b>	Anti-IL-5 receptor humanized antibody	Phase I		Asthma	Injection	Developed In-house	Being developed by MedImmune as MEDI-563 worldwide except in Japan and other Asian countries POTELLIGENT®
Other	<b>KHK6188</b>	Cannabinoid CB2 receptor agonist	Phase I		Neuropathic pain	Oral	Developed In-house	
	<b>KRN23</b>	Anti-FGF23 fully human antibody		Phase I in USA	X-linked hypophosphatemic rickets/osteomalacia (XLH)	Injection	Developed In-house	

(※) KW-0761 is outlicensed to Amgen Inc. on March 6th, 2008, with an exclusive right to develop and commercialize KW-0761 worldwide, except in Japan, Korea, China and Taiwan. Kyowa Hako Kirin has retained the development and commercialization rights in these countries. In 2010, KHK paid Amgen US\$20M for the buy-out of Amgen's option to assume the development and commercialization of KW-0761 in oncology setting in Amgen's licensed territory, which was granted under the License Agreement.

Updated since Apr 27th, 2011 (Area, Stage, Filed, Approved, Launched etc.)

★ New indication